OST-HER2 Regulatory Progress Advances Osteosarcoma Care
NEW YORK, NEW YORK, UNITED STATES — February 17, 2026 OS Therapies has announced a major global regulatory update...
Immunotherapy
Advertisement
Nektar Raises $460M to Advance Immunotherapy Pipeline
SAN FRANCISCO, Feb. 13, 2026 — Nektar Therapeutics announced the successful closing of a $460 million underwritten public offering,...
Anixa Advances CAR-T Dose Escalation in Ovarian Cancer
SAN JOSE, Calif., Feb. 9, 2026 — Anixa Biosciences reported encouraging survival observations from its ongoing Phase 1 ovarian...
FDA Expands Yescarta Label in CNS Lymphoma Care
Santa Monica, California — February 6, 2026 Kite, a Gilead Company, has announced that the U.S. Food and Drug...
Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Advertisements
Third Arc Bio Secures $52M to Advance Antibody Pipeline
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
Canada Recommends Opdivo Plus Yervoy for Liver Cancer Care
OTTAWA, Canada, February 2026 — Canada’s Drug Agency (CDA-AMC) has issued a conditional reimbursement recommendation for Opdivo® (nivolumab) plus...
Artiva Highlights Durable AlloNK Outcomes at 2026 Tandem
San Diego, California, January 21, 2026 — Artiva Biotherapeutics, a clinical-stage biopharmaceutical company focused on allogeneic natural killer (AlloNK)...
Nous-209 Vaccine Shows Promise for Cancer Interception
ROME and BASEL, January 2026 — Nouscom has reported compelling clinical evidence supporting the potential of NOUS-209, a neoantigen-directed...
CG Oncology Advances Phase 3 Timeline for NMIBC Trial
IRVINE, California | January 9, 2026 — CG Oncology, Inc., a late-stage clinical biopharmaceutical company, has announced an accelerated...
Advertisement
